title: Emerging antiretroviral drugs.
abstract: BACKGROUND
  The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including low daily pill burden, friendly metabolic profile, lack of (or few) drug interactions and high resistance barrier.
  
  
  METHODS
  Updated summary of evidence-based information about the efficacy and safety of the most recently approved or forthcoming antiretroviral agents is provided. All data on antiretrovirals in the most advanced development stages available in peer-reviewed journals or presented at international meetings has been reviewed.
  
  
  CONCLUSIONS
  Dolutegravir displays greater barrier to resistance and requires simpler administration than other currently existing drugs within the same class. Newer pharmacoenhancers (i.e., cobicistat), CCR5 antagonists (i.e., cenicriviroc) and nucleotide prodrugs (i.e., tenofovir alafenamide fumarate) show promising results and will expand the current HIV armamentarium. The development of newer once-daily, single-tablet coformulations will further improve drug adherence and maximize the success of antiretroviral therapy.
authors.affiliation: Hospital Carlos III, Department of Infectious Diseases, C/Sinesio Delgado 10, Madrid, 28029 , Spain vsoriano@dragonet.es.
authors.forename: José Vicente
authors.initials: JV
authors.lastname: Fernández-Montero
authors.forename: Eugenia
authors.initials: E
authors.lastname: Vispo
authors.forename: Vicente
authors.initials: V
authors.lastname: Soriano
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D017277:Drug Approval; D015195:Drug Design; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D055118:Medication Adherence
chemical_list: D019380:Anti-HIV Agents